We came across a bullish thesis on Erasca, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ERAS. Erasca, Inc.'s share was trading at $12.39 as of February 19th.
[caption id="attachment_1617126" align="aligncenter" width="768"]Erasca, Inc. (ERAS) is a clinical-stage biotech focused on RAS/MAPK-driven cancers, a large and unmet medical need affecting millions globally each year. The company operates in the high-growth oncology sector, which benefits from strong...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.